| 1 | 22693356 | Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling. | Clin Cancer Res | 2012 Aug 1 |
5 |
| 2 | 26796063 | Human ATP-Binding Cassette Transporter ABCG2 Confers Resistance to CUDC-907, a Dual Inhibitor of Histone Deacetylase and Phosphatidylinositol 3-Kinase. | Mol Pharm | 2016 Mar 7 |
27 |
| 3 | 27829312 | CUDC-907 Promotes Bone Marrow Adipocytic Differentiation Through Inhibition of Histone Deacetylase and Regulation of Cell Cycle. | Stem Cells Dev | 2017 Mar 1 |
5 |
| 4 | 27980108 | Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers. | Mol Cancer Ther | 2017 Feb |
9 |
| 5 | 28139498 | Enhanced efficacy of 5-fluorouracil in combination with a dual histone deacetylase and phosphatidylinositide 3-kinase inhibitor (CUDC-907) in colorectal cancer cells. | Saudi J Gastroenterol | 2017 Jan-Feb |
1 |
| 6 | 28147336 | Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma. | Oncotarget | 2017 Feb 21 |
5 |
| 7 | 28600475 | Dual Inhibition of HDAC and Tyrosine Kinase Signaling Pathways with CUDC-907 Inhibits Thyroid Cancer Growth and Metastases. | Clin Cancer Res | 2017 Sep 1 |
9 |
| 8 | 28819699 | CUDC-907, a dual HDAC and PI3K inhibitor, reverses platinum drug resistance. | Invest New Drugs | 2018 Feb |
7 |
| 9 | 29760046 | Dual HDAC and PI3K Inhibition Abrogates NFκB- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas. | Cancer Res | 2018 Jul 15 |
6 |
| 10 | 30224636 | CUDC-907 displays potent antitumor activity against human pancreatic adenocarcinoma in vitro and in vivo through inhibition of HDAC6 to downregulate c-Myc expression. | Acta Pharmacol Sin | 2019 May |
6 |
| 11 | 30353642 | CUDC-907 blocks multiple pro-survival signals and abrogates microenvironment protection in CLL. | J Cell Mol Med | 2019 Jan |
19 |
| 12 | 30696721 | Clinicopathological and Preclinical Findings of NUT Carcinoma: A Multicenter Study. | Oncologist | 2019 Aug |
7 |
| 13 | 30819918 | Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia. | Haematologica | 2019 Nov |
6 |
| 14 | 31545402 | CUDC‑907 reverses pathological phenotype of keloid fibroblasts in vitro and in vivo via dual inhibition of PI3K/Akt/mTOR signaling and HDAC2. | Int J Mol Med | 2019 Nov |
11 |
| 15 | 31901955 | Effect of dual inhibition of histone deacetylase and phosphatidylinositol-3 kinase in Philadelphia chromosome-positive leukemia cells. | Cancer Chemother Pharmacol | 2020 Feb |
6 |
| 16 | 32165486 | The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia. | Haematologica | 2021 May 1 |
6 |
| 17 | 32200503 | CUDC-907 enhances TRAIL-induced apoptosis through upregulation of DR5 in breast cancer cells. | J Cell Commun Signal | 2020 Dec |
18 |
| 18 | 32459381 | CUDC-907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: Antitumour activity and molecular mechanism of action. | J Cell Mol Med | 2020 Jul |
8 |
| 19 | 32780889 | The role of CUDC-907, a dual phosphoinositide-3 kinase and histone deacetylase inhibitor, in inhibiting proliferation of adult T-cell leukemia. | Eur J Haematol | 2020 Dec |
7 |
| 20 | 32943605 | Dual inhibition of HDAC and tyrosine kinase signaling pathways with CUDC-907 attenuates TGFβ1 induced lung and tumor fibrosis. | Cell Death Dis | 2020 Sep 17 |
6 |
| 21 | 33000123 | Targeting Corticotroph HDAC and PI3-Kinase in Cushing Disease. | J Clin Endocrinol Metab | 2021 Jan 1 |
4 |
| 22 | 33069237 | The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer. | J Exp Clin Cancer Res | 2020 Oct 17 |
7 |
| 23 | 33077264 | Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors. | Eur J Med Chem | 2021 Jan 1 |
1 |
| 24 | 33280267 | Pluripotent stem cell-based screening identifies CUDC-907 as an effective compound for restoring the in vitro phenotype of Nakajo-Nishimura syndrome. | Stem Cells Transl Med | 2021 Mar |
2 |
| 25 | 33392641 | Antitumor activity and mechanism of resistance of the novel HDAC and PI3K dual inhibitor CUDC-907 in pancreatic cancer. | Cancer Chemother Pharmacol | 2021 Mar |
8 |
| 26 | 33402194 | Correction to: The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer. | J Exp Clin Cancer Res | 2021 Jan 5 |
1 |
| 27 | 33663586 | Targeting phosphoinositide 3-kinases and histone deacetylases in multiple myeloma. | Exp Hematol Oncol | 2021 Mar 4 |
4 |
| 28 | 33757580 | Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma. | J Exp Clin Cancer Res | 2021 Mar 23 |
1 |
| 29 | 34099621 | The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML. | Blood Cancer J | 2021 Jun 7 |
2 |
| 30 | 34776939 | Therapeutic Potential of CUDC-907 (Fimepinostat) for Hepatocarcinoma Treatment Revealed by Tumor Spheroids-Based Drug Screening. | Front Pharmacol | 2021 |
4 |
| 31 | 35205815 | Dual Targeting of PI3K and HDAC by CUDC-907 Inhibits Pediatric Neuroblastoma Growth. | Cancers (Basel) | 2022 Feb 20 |
3 |
| 32 | 35291899 | CIITA expression is regulated by histone deacetylase enzymes and has a role in α-synuclein pre-formed fibril-induced antigen presentation in murine microglial cell line. | Immunopharmacol Immunotoxicol | 2022 Jun |
6 |